Skip to content

Molecular regulatory mechanism of neuropathic pain caused by herpes zoster based on omics

Molecular regulatory mechanism of neuropathic pain caused by herpes zoster based on omics

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200057765
Enrollment
Unknown
Registered
2022-03-17
Start date
2022-03-21
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postherpetic neuralgia

Interventions

acute group:None
chronic phase group:None
control group:None

Sponsors

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria of the disease group: (1) Patients with herpes zoster in the acute stage (within one month of onset) or chronic stage (over six months of onset); (2) Aged >=18 years; (3) NRS (Pain Numerical Scale) score >=4 points; (4) Sign informed consent. 2. Inclusion criteria of the control group: (1) Healthy people without any other serious diseases; (2) Aged >=18 years;(3) Do not suffer from any form of neuralgia or nerve injury; (4) The score of NRS (Pain Numerical Scale) was between 0 and 1; (5) Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe diseases of the liver or other organs, serious and unstable heart, lung, vascular, gastrointestinal, neurological, endocrine, psychiatric disorders (which may lead to memory impairment, disorientation or inaccurate reporting) or metabolic diseases; ? 2. They have mental disorders that prevent them from correctly evaluating their own conditions, such as the degree of pain, quality of life and adverse reactions; ? ? 3. Patients suffering from cerebral stroke or any other form of cerebrovascular diseases do not have other forms of neuralgia or nerve injury; 4. Diabetic patients; 5. Vulnerable groups, including persons with mental illness, persons with cognitive impairment, critically ill patients, minors, pregnant women, etc.

Design outcomes

Primary

MeasureTime frame
Blood/Urine metabolomics;Blood/Urine peptidomics;Blood/Urine circRNA;Expression levels of differential metabolites or peptides or circRNAs;

Countries

China

Contacts

Public ContactChen Gang
chengang120@zju.edu.cn+86 13757118681

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026